Men's Health News

RSS

Low testosterone levels can impact sleep quality

At 30 years old, male testosterone levels drop by one to two percent annually. By age 40, men's quality of sleep begins to diminish. Could there be a link between decreased testosterone and reduced sleep?

15 May 2010

Rich Canadian men increase their likelihood of being overweight

In Canada, in stark contrast with the rest of the world, wealthy men increase their likelihood of being overweight with every extra dollar they make. The new study was led by Nathalie Dumas, a graduate student at the University of Montreal Department of Sociology, and presented at the annual conference of the Association francophone pour le savoir.

15 May 2010

Multivitamin and mineral supplements improve mood, mental performance in healthy males: Study

The effects of multivitamins are most often researched in the elderly. This is one of very few studies to assess the relationship between supplementation with vitamins/minerals and psychological functioning in healthy groups of non-elderly adults. This study shows how a proprietary multivitamin and mineral supplement improves mood and mental performance while also reducing stress, mental tiredness and fatigue in healthy males.

14 May 2010

RMEI, PIM sponsor continuing education series on castration-resistant prostate cancer

Castration-resistant prostate cancer (CRPC), defined as tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Current treatment regimens are complicated by toxicities and a low rate of relapse-free survival. Many novel therapies in clinical trials offer hope for patients with this challenging diagnosis. Healthcare professionals who are treating CRPC must stay abreast of these emerging therapies to ensure optimal care for these patients.

14 May 2010

Rexahn Pharmaceuticals announces Phase IIb clinical trial of Zoraxel for ED

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will initiate a Phase IIb clinical trial for ZoraxelTM in the treatment of erectile dysfunction (ED).

13 May 2010

25% of adults quit their overactive bladder medication: Study

Study of 5,392 adults found that a quarter had quit their overactive bladder medication, with nine out of ten saying it didn't work as expected or they couldn't tolerate it. A follow-up study found that being a current smoker raised the risk of quitting by 80%, having an enlarged prostate by 74% and believing that bladder medication caused side effects by 111%.

13 May 2010

Researchers develop new technology to manage prostate cancer treatment

Researchers at Queen's University have developed a new way of performing lab tests that could improve the way doctors manage prostate cancer treatment. It will allow them to identify with unprecedented accuracy losses of a gene called PTEN that is associated with an aggressive group of prostate cancers.

13 May 2010

Update on Nymox Pharmaceutical's Phase 3 program for NX-1207

Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia. The most recent Safety Monitoring Committee meeting of April 30, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 indicated no significant safety concerns for the trials to date.

12 May 2010

Allergic conditions that result from hyper reactive immune system may lower cancer risk: Study

If you have asthma or eczema, your hyper reactive immune system may lower your risk of some of the most common types of cancer, according to a study published this month in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology.

12 May 2010

Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localized prostate cancer.

12 May 2010

Older Americans staying sexually active but not practicing safe sex

Sexual activity continues to thrive with the 45+ demographic according to a new AARP sex survey, Sex, Romance, and Relationships: AARP Survey of Midlife and Older Adults, released today. However, older adults are not necessarily practicing what they preach to younger generations, with results showing a low use of protection among sexually active dating singles with only one in five reporting use of condoms regularly.

11 May 2010

UNC-CH awarded $100,000 Grand Challenges Explorations grant for study of ultrasound as a contraceptive

The University of North Carolina at Chapel Hill has received a $100,000 Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation. The grant will support an innovative global health research project conducted by James Tsuruta, PhD, and Paul Dayton, PhD, titled "Ultrasound as a long-term, reversible contraceptive."

11 May 2010

Medical options to help prostate cancer patients make informed treatment decisions

While the dreaded words "You have prostate cancer" often leave patients confused, the impact of the diagnosis can extend to the entire family, especially wives, says a top expert.

10 May 2010

Experts to present latest research on prostate cancer and related conditions

WHAT: This symposium features a renowned faculty of clinicians and researchers who will present leading-edge information on the best standards of care in managing the full spectrum of prostate cancer and related conditions.

10 May 2010

Preoperative MRI helps spare erectile function, continence after RALP for prostate cancer

Preoperative prostate magnetic resonance imaging (MRI) can help urologic surgeons spare the neurovascular bundle (NVB) (which controls a man's erectile function and continence) during a robotic assisted laparoscopic prostatectomy (RALP) for the treatment of prostate cancer, according to a study to be presented at the ARRS 2010 Annual Meeting in San Diego, CA.

7 May 2010

Australia’s first ever health policy for men

Prime Minister Kevin Rudd yesterday announced Australia’s first ever men’s health policy called the “National Male Health Policy”. He said in the announcement during a visit to the Whittlesea Men's Shed in Victoria, “They either think that they're invincible that they can just tough it out…'They don't like talking about it usually, and frankly, the problem with all that is it makes it really hard to deal with men's health problems before they become too serious.” He felt this move was long due. He added, “'It's a pretty important time that we do that, we're probably about 110 years late.”

6 May 2010

FDA approves Provenge for treating men with advanced prostate cancer

The US Food and Drug Administration has approved a new 'cancer vaccine' for treating men with advanced prostate cancer.

6 May 2010

Nymox Pharmaceutical announces new positive results from long term outcome study of NX-1207 for BPH

Nymox Pharmaceutical Corporation today announced new 2010 positive results from a long term outcome study of NX-1207 for benign prostatic hyperplasia (BPH). The study evaluated symptomatic progress of U.S. patients involved in the Company's NX02-0012 and NX02-0013 Phase 1-2 studies of NX-1207 initially undertaken in 2003. Patients treated with NX-1207 were followed-up on an unselected and as available basis and assessed for symptomatic improvement, treatment outcomes, and durability of efficacy 6 ½ years after a single treatment with NX-1207.

5 May 2010

LA BioMed receives $1.5M in grant to study contraceptive for men

As the birth control pill marks its 50th birthday this month, Los Angeles Biomedical Research Institute announced today that it has received $1.5 million in grant funding to study a contraceptive for men that uses a combination of two hormonal gels applied to the skin of the arm and abdomen.

4 May 2010

Obese men more likely to have low testosterone than non-obese men: HIM study

Obesity, a condition linked to heart disease and diabetes, now appears to be associated with another health problem, but one that affects men only -- low testosterone levels.

4 May 2010

Men's Health News

Low testosterone levels can impact sleep quality

Rich Canadian men increase their likelihood of being overweight

Multivitamin and mineral supplements improve mood, mental performance in healthy males: Study

RMEI, PIM sponsor continuing education series on castration-resistant prostate cancer

Rexahn Pharmaceuticals announces Phase IIb clinical trial of Zoraxel for ED

25% of adults quit their overactive bladder medication: Study

Researchers develop new technology to manage prostate cancer treatment

Update on Nymox Pharmaceutical's Phase 3 program for NX-1207

Allergic conditions that result from hyper reactive immune system may lower cancer risk: Study

Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients

Older Americans staying sexually active but not practicing safe sex

UNC-CH awarded $100,000 Grand Challenges Explorations grant for study of ultrasound as a contraceptive

Medical options to help prostate cancer patients make informed treatment decisions

Experts to present latest research on prostate cancer and related conditions

Preoperative MRI helps spare erectile function, continence after RALP for prostate cancer

Australia’s first ever health policy for men

FDA approves Provenge for treating men with advanced prostate cancer

Nymox Pharmaceutical announces new positive results from long term outcome study of NX-1207 for BPH

LA BioMed receives $1.5M in grant to study contraceptive for men

Obese men more likely to have low testosterone than non-obese men: HIM study

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News